2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Point Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy talabostat, pemetrexed - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 3 | Terminated | Point Therapeutics | 400 | 2006-02-01 | 2007-06-08 |
| Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy talabostat mesylate, docetaxel - Carcinoma, Non-Small Cell Lung | Phase 3 | Terminated | Point Therapeutics | 400 | 2006-01-01 | 2007-06-08 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2)
Docetaxel (1) · PT-100 dipeptide (1) · Pemetrexed (1) · talabostat (1)
United States (2)